Local cerebral metabolic rate for glucose was studied with '8F-2-fluorr+2-deoxy-D-glucose and positron emission tomography (PET) in 22 patients with Friedreichs ataxia and 23 age-matched normal control subjects. The diagnosis of Friedreich's ataxia was established by the history and physical findings and by excluding other diseases through laboratory investigations. PET studies revealed a statistically significant widespread increase of local cerebral metabolic rate for glucose in the brains of patients with Friedreich's ataxia who were still ambulatory, in comparison with normal control subjects. Nonambulatory patients with Friedreich's ataxia, in comparison with normal control subjects, had significantly increased local cerebral metabolic rates for glucose in the caudate and lenticular nuclei, but not in the other structures studied. The rate was significantly greater in ambulatory patients with Friedreich's ataxia than in nonambulatory patients in all structures studied except the caudate and lenticular nuclei. The data suggest that early in the course of Friedreich's ataxia, the local cerebral metabolic rate for glucose is increased extensiveIy in the central nervous system, and as the disease progresses, it decreases in a regionally specific manner. 
FA develop diabetes mellitus IS].
The principal neuropathological changes in FA involve the peripheral nerves and the spinal cord {l,
4, 8-1 1). Degeneration occurs in peripheral sensory
nerves, dorsal root ganglia, and dorsal roots. Within the spinal cord, there is degeneration of posterior columns, lateral corticospinal tracts, and dorsal and ventral spinocerebellar tracts. The cerebellum and brainstem have been described as normal { 1 1 ], but in some patients there is shrinkage of the pons and medulla C9, lo]. Occasional patients show patchy atrophy of the Purkinje cells, and in many there is degeneration of neurons in the dentate nuclei [lo] . Degenerative changes may also occur in the reticular and vestibular nuclei of the brainstem C9, lo].
Many biochemical abnormalities have been reported in fibroblasts, leukocytes, or muscle tissue from patients with FA, but some of these findings axe controversial. Deficiencies in activity of the pyruvate dehydrogenase complex and alpha ketoglutarate dehydrogenase complex have been described {12, 131. Other abnormalities reported include deficiency of mitochondrial malic enzyme activity [14, 151 and of serum lipoprotein lipase ElGI and abnormalities of erythrocyte membrane phospholipids, plasma catecholamines, and leukocyte glutamate dehydrogenase activity C51.
In most patients with FA, the characteristic history and physical findings make the diagnosis relatively straightforward El-41. In patients with progressive ataxia whose history and physical findings differ from those typical of FA, however, the diagnosis is often difficult and requires extensive laboratory testing. T h e differential diagnosis of these patients includes malformations, degenerations, demyelinative diseases, neoplasms, remote effects of neoplasms, vascular diseases, and metabolic abnormalities { 1, 171.
Positron emission tomography (PET) with I8F-2-fluoro-2-deoxy-D-glucose (ISF-FDG) has been used to study local cerebral metabolic rate for glucose (1CMRglc) in the central nervous system of patients with olivopontocerebellar atrophy, another degenerative disease causing ataxia [18-20} . A distinctive pattern of hypometabolism was found in the brainstem and cerebellum without involvement of the cerebral cortex, basal ganglia, or thalamus. T h e present study was undertaken to determine whether a unique pattern might be found in patients with FA as well. De 
Materials and Methods
We studied 22 patients with FA and 23 normal control subjects (Table I) . The studies were approved by the institutional review board, and informed consent was obtained from all subjects. Among the patients with FA, the duration of illness averaged 18 * 7 years and ranged from 6 to 30 years. Ten patients had one or more affected siblings, 11 had no affected relatives, and 1 patient had a cousin who may have FA. The normal control subjects had no history of neurological disease and no significant abnormalities on neurological and general physical examination. The patients and normal control subjects were taking no medication known to affect central nervous system (CNS) function or to cause CNS side effects and subjects with a history of alcoholism were excluded.
The diagnosis of FA was made on the basis of the history, physical examination, neurological examination, and laboratory tests to exclude other diseases. Required findings included ataxia of limb movements and of gait if the patients were still ambulatory; weakness of the lower extremities; ataxic dysarthria; decreased or absent muscle stretch reflexes in the lower extremities; extensor plantar reflexes; and decreased position and vibration sense in the lower extremities. The diagnosis was supported by the findings of scoliosis, pes cavus, decreased pinprick and light touch sensation in the distal parts of the extremities, and atrophy of the distal limb PET studies of normal control subjects and patients with FA were performed with the subjects lying supine, awake, immobile, not speaking, and blindfolded in a quiet room. They were maintained under these conditions from 5 minutes before injection until completion of the scan. '*F-FDG was synthesized by an adaptation of the method of Shiue and associates {26] or of Hamacher and coworkers 1271. Radiochemical purity was greater than 95%. Scans were performed 30 to 75 minutes after intravenous injection of 5 to 10 mCi of "F-FDG and lasted for 8 to 12 minutes. Each subject was placed in a headholder that maintained the head immobile throughout the study. The head was aligned along the orbitomeatal line with a laser. PET scans were performed with a TCC PCT 4600A tomograph having an inplane resolution of 11-mm full width at half maximum (FWHM) and a Z-axis resolution of 9.5-mm PWHM. Five planes with 11.5-mm center-to-center separation were imaged simultaneously.
Four sets of scans were taken per patient, including two interleaved sets through lower brain levels and two interleaved sets through higher brain levels for a total of 20 slices, each separated by 5.75 mm. Attenuation correction was calculated by fitting ellipses to the contour of the scalp outline and modified to account for attenuation from the headholder and skull. Blood samples were collected from one radial artery. 1CMRglc was calculated with a three compartment model and single-scan approximation, with gray matter kinetic constants derived from normals.
Regions of interest (ROIs) were studied in the cerebral cortex, basal ganglia, thalamus, cerebellar hemispheres, cerebellar vermis, mesencephalon, and pons. Data from the cerebral cortex were obtained by measuring ICMRglc in the cortical rim from six consecutive slices beginning with the lowest slice containing the basal ganglia. This was accomplished with an algorithm that detects the outer edge of the cortical rim on images that have been passed through a contrast-enhancing filter. The algorithm then identifies a cortical strip on the original image that extends inward from this edge until either the metabolic rate drops below the value on the outer edge of the rim or the strip reaches a width of 15 mm. The mean metabolic rate was computed for each of the ROIs and the final value was a weighted mean of the values from the six individual slices. The ROIs for the basal ganglia consisted of an 11 x 11-mm square on each side of the caudate nucleus and an 11 x 15-mm parallelogram on each side of the lenticular nucleus (putamen and globus pallidus). The other ROIs consisted of an 11 x 11-mm square on each side of the thalamus, a 22 x 11-mm parallelogram on each cerebellar hemisphere, and an 11 x 18-mm rectangle on the cerebellar vermis. For analysis of the mesencephalon and pons, a three-dimensional image set consisting of planes spaced at 3.75 mm intervals in the rostrocaudal direction was generated by interpolation of the two-dimensional images. A midsagittal image, 11 mm in thickness, was derived from thls image set. The resulting volume of interest for the mesencephalon was an 11 X 11 X 7.5-mm right parallelepiped, while that for the pons was a 15 x 11 X 15-mm right parallelepiped. The ROIs were centered over a local peak in 1CMRglc. For reference, an individual image element (pixel) is 3.75 x 3.75 mm in size. Data were obtained from two slices containing the cerebellum and branstem, from one slice containing the thalamus, and from one slice containing the basal ganglia. ROIs from the cerebellar vermis were posterior to the fourth ventricle, as determined by direct visualization of the ventricle. An index of brain volume was developed to compare the patients with FA and the control subjects. The mean crosssectional area of the brain from the two largest adjacent PET slices was measured, and this value was raised to the 312 power.
Statistical analysis was performed with two-tailed Student's t tests, analysis of variance, the Newman-Keuls test, and Spearman rank correlation analysis. A p value of 0.05 or less was taken as significant. 
Results
Mean lCMRglc for the entire FA group was 7% to 28% greater than that of the control group for the structures analyzed. Statistical testing revealed significantly increased lCMRglc in the patients with FA, compared with the control subjects, in the cerebral cortex, caudate nucleus, and lenticular nucleus, but not in the thalamus, cerebellar vermis, cerebellar hemispheres, or brainstem ( Table 2) . To examine the relationship between the severity of the neurological disorder and ICMRglc, we divided the patients into two groups, ambulatory and nonambulatory. The two groups were equal in age at the time of the study, but the ambulatory patients had a significantly later age of onset than did the nonambulatory patients ( Table 3) . Mean lCMRglc for the ambulatory group was 23% to 34% greater than that of the control group for the structures analyzed (Table 4, Fig 1) . lCMRglc in the ambulatory group was significantly increased, compared with the normal control subjects, in all structures studied except the pons. In contrast, mean lCMRglc for the nonambulatory group ranged from 4% less to 24% greater than that of the normal control group for the structures analyzed. lCMRglc was significantly higher in nonambulatory patients than in normal controls for the basal ganglia, but not for the other structures (see Table 4 ). 1CMRglc was significantly greater in the ambulatory patients than in the nonambu!atory group in all structures studied except for the cerebral cortex, where the difference approached significance, and in the basal ganglia (see Table 4 ). The differences between control, ambulatory, and nonambulatory groups are portrayed in Figure 2 , in which the data in the two FA groups are normalized to the values of the control group. To determine whether differences in lCMRglc between the sexes contributed to the observed differences between groups, we compared ICMRglc in patients with FA and normal control subjects using analysis of variance with sex and disease group as f xtors ( Table 5 ). The results revealed that sex was not a significant factor for any region. Disease group was a significant factor for the cerebral cortex, caudate nucleus, and lenticular nucleus, but not for the thalamus, cerebellum, or brainstem. There was no significant interaction between disease group and sex for ICMRglc values from any region.
Since FA is a progressive disorder, we examined lCMRglc as a function of age and duration of symptoms. lCMRglc declined significantly with increasing age in the caudate nucleus (Spearman rank correlation patients had significantly higher 1CMRglc than nonambulatory patients for all structures except the basal ganglia. Neither the sexes nor the ages of the patients was a significant factor in the findings. The age of onset of symptoms was signhcantly greater in patients who were ambulatory at the time of the study than in the nonambulatory patients. This difference is most likely explained on the basis of selection bias. Age 18 was the minimum age at which normal control subjects and patients were eligible for our study in accordance with institutional policy regarding studies with radionuclides in children. In a slowly progressive disease such as FA, patients who remain ambulatory over the age of 18 are likely to be those with a late age of onset. It may also be that our ambulatory patients had intrinsically milder disease or slower progression of disease than our nonambulatory patients. We cannot exclude the possibility that our group of ambulatory patients represents, in part, a different phenotype from the nonambulatory group. Variations in phenotype are known to occur even in kindreds that inherit the same abnormal gene {8, 25, 28, 291.
Our findings may indicate that, early in the course of FA, glucose metabolic rate is increased broadly in the CNS, and as the disease progresses, metabolic rate decreases. The decrease is nonuniform, with the basal ganglia maintaining a higher metabolic rate with disease progression than the other structures studied. The increased metabolism may reflect a fundamental biochemical defect in FA, while the decline in metabolic rate with disease progression may be due to loss of neurons and synaptic terminals. This would explain the finding of more substantially increased metabolic rate in ambulatory than in nonambulatory patients, since typically with disease progression, FA patients lose the ability to walk.
The possibility that the finding of glucose hypermetabolism is artifactual must be considered. The major potential sources of error are FA-specific alterations in 18F-FDG rate constants between subject groups, and smaller brain size in patients with FA than in normal control subjects. The possibility that FAspecific alterations in the rate constants affected our data seems unlikely, since changes in rate constants that cause major errors in the single-scan approximation used to evaluate lCMRglc have not been found in any progressive degenerative neurological disease. We found that patients with FA have smaller brain volumes than normal control subjects; however, this finding is not likely to account for the glucose hypermetabolism. Hatazawa and colleagues {so] found in normal subjects that lCMRglc is inversely proportional to brain volume. Since the small brain volume in patients with FA presumably results from their disease process, it is questionable whether the same relationship applies to them. This relationship clearly does not apply to patients with Alzheimer's disease, who have a decreased volume associated with hypometabolism. Even if this relationship were to apply to patients with FA, the 75% decrease in brain volume compared to normal subjects would account for only a 7% increase in lCMRglc, yet we observed a 23% to 34% increase in lCMRglc in ambulatory patients with FA, compared with normal subjects. We cannot exclude the possibility that an increased value for the lumped constant for fluorodeoxyglucose in FA could partially or completely account for our finding of increased lCMRglc values, which were calculated assuming a normal value for the lumped constant (0.51). An increase in the lumped constant for 2-deoxyglucose has been described in hypoglycemia 142, 431 and is thought to be due to a shift in the ratelimiting step from phosphorylation to transport. Conceivably, an increased value of the lumped constant in FA could share the same mechanism. Alterations in the lumped constant could influence our findings in either of two possible ways. First, the lumped constant could be increased in patients with early disease and could then decline with disease progression. This possibility is unlikely because changes that may occur with disease progression, such as loss of neurons and synaptic connections, would not be expected to reverse the change in the lumped constant substantially. Second, the lumped constant could be increased in all patients with FA, and the decrease in lCMRglc values in nonambulatory patients compared with ambulatory patients could represent a true decline in glucose metabolism associated with loss of neuronal elements.
The difference in metabolism between ambulatory and nonambulatory patients may be due to loss of neuronal connections as the disease progresses. Study of the degree of atrophy in ambulatory as compared with nonambulatory patients in anatomical scans would perhaps clarify this issue. The findings of glucose hypermetabolism within certain structures in ambulatory but not in nonambulatory patients resulted from examining a cross-section of patients. Our speculation that glucose metabolism decreases with progression of FA may be strengthened by longitudinal follow-up of individual patients with repeated testing. We have not studied patients with FA early in the disease process because our PET studies are limited to patients and normal subjects age 18 and older. From our present results, we cannot determine whether patients early in the course of FA have a greater degree or a lesser degree of hypermetabolism than our ambulatory group, most of whom are at an intermediate stage of the disease with a moderate level of disability. Similarly, our data do not make clear whether metabolism declines to a level below that of normal subjects. Examination of patients with FA toward the end of their disease process would be necessary to establish this.
In previous PET studies, the finding of glucose hypermetabolism in steady state is unusual. Increased glucose metabolism has been reported in Down's syndrome [44, 451 , anorexia nervosa 1461, and autism f471, but in a recent report no definitive evidence of increased metabolism was found in autism {48], and the finding in Down's syndrome is now thought to be artifactual {491. Thus, FA is one of only a few conditions demonstrated through PET to involve hypermetabolism in steady state.
